NCT03851926

Hypofractionated Radiotherapy for Prostate Cancer

Hypofractionated Radiotherapy for Prostate Cancer in 20 Sessions

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 300 (actual)
• Sponsor: Consorci Sanitari de Terrassa · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Radiotherapy is a standard definitive treatment for men with localized prostate cancer. Recent improvements in technology allow high doses of radiation to be delivered to the prostate in less days with lower doses to surrounding healthy tissues, trying to reduce side effects. This study is being proposed to evaluate the use of moderate hypofractionated volumetric radiotherapy in localized prostate cancer patients and assessing treatment -related later adverse events using the CTCAE 4.0

Detailed description

Recent evidence suggests that the same or better outcomes might be achieved in prostate cancer by ussing a higher dose of radiation per fraction ( 3Gy) with the consequent decrease in total days Quality of life outcomes as well as gastrointestinal and genitourinary late toxicities will be analyzed. It is thought that this regimen will produce comparable findings and would result in substantial health care cost savings, as well as, be more convenient for patients.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
RADIATION	Hypofractionated volumetric radiotherapy in 20 fractions	Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.

Timeline

• Start date: 2016-10-05
• Primary completion: 2021-10-05
• Completion: 2021-10-05
• First posted: 2019-02-22
• Last updated: 2023-02-10

Locations

1 site across 1 country: Spain